Kosan's Chief Executive Officer resigns
Robert Johnson Appointed Acting CEO
Robert Johnson joined Kosan in 2000, when the company was just establishing its development organization. Since Dr. Johnson has joined Kosan, the company has filed five investigational new drug applications (INDs), has five product candidates in Phase I and II clinical trials and has built experienced pre-clinical and clinical groups from the ground up. The Board has full confidence in Dr. Johnson's ability to lead the company through this transition.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.